Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21026
Abstract: e21026Background: Osimertinib has recently become standard of care for advanced, EGFR-mutated NSCLC, and usage in frail populations may incur precautions. Methods: The TREM-study is an investigator... read more here.
Keywords: platelet count; count increase; drop blood; increase creatinine ... See more keywords